Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression

Jiajia Zhou, Xiaogeng Deng, Xiaoyu He, Yu Zhou, Min Yu, Wenchao Gao, Bing Zeng, Quanbo Zhou, Zhihua Li, Rufu ChenInternational Journal of Oncology 2014 · DOI

Abstract

Multidrug resistance (MDR) is one of the major reasons for the failure of liver cancer chemotherapy, and its suppression may increase the efficacy of chemotherapy. NANOG plays a key role in the regulation of embryonic stem cell self-renewal and pluripotency. Recent studies reported that NANOG was abnormally expressed in several types of tumors, indicating that NANOG is related to tumor development. However, the correlation between NANOG and liver cancer chemoresistance remains uncertain. In this study, RNA interference technology was employed to knock down NANOG expression in HepG2 human liver cancer cells. We found that the knockdown of NANOG expression in NANOG siRNA-transfected HepG2 cells resulted in decreased colony formation rate and cell migration compared to control HepG2 cells. In addition, HepG2 cells were treated with doxorubicin to evaluate the chemosensitivity to doxorubicin. We found that the doxorubicin sensitivity of HepG2 cells was increased with downregulation of NANOG expression. The expression of MDR1 at both mRNA and protein levels was decreased in HepG2 cells when NANOG was knocked down. These findings suggest that the knockdown of NANOG in HepG2 human cells resulted in decreased MDR1 expression and increased doxorubicin sensitivity, and NANOG could be used as a novel potential therapeutic target to reverse multidrug resistance of liver cancer.

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. While surgery is the preferred treatment, many patients are not candidates for it, leaving chemotherapy as the primary alternative. Unfortunately, liver cancer is notoriously multidrug resistant (MDR). A major driver of this resistance is the MDR1 gene, which produces P-glycoprotein—a molecular "sump pump" that sits on the cell membrane and flushes out chemotherapeutic agents like doxorubicin before they can kill the cell.

This study investigates whether NANOG, a transcription factor usually associated with embryonic stem cell "stemness," regulates this resistance. While NANOG is known to be overexpressed in various tumors, its specific role in liver cancer's drug-evasion tactics remained unclear. Researchers hypothesized that by silencing NANOG, they could reduce MDR1 expression and restore chemosensitivity.

Methods

The researchers utilized the HepG2 human liver cancer cell line (sourced from ATCC) as their primary model. To investigate NANOG's function, they employed several molecular biology techniques:

  • RNA Interference (siRNA): Specific small interfering RNAs were used to knock down the expression of NANOG mRNA (GenBank accession: NM_024865.2).
  • Quantitative Analysis: Real-time RT-PCR and Western blotting were used to confirm the reduction of NANOG and MDR1 at both the messenger RNA and protein levels.
  • Functional Assays: Colony formation assays measured clonogenicity, while Transwell migration assays assessed invasive potential. Cell viability and chemosensitivity were quantified using the CCK8 assay after exposure to doxorubicin.

Results

Successful Silencing of NANOG

The siRNA treatment effectively reduced NANOG expression. Quantitative RT-PCR demonstrated a significant decrease in NANOG mRNA levels in the siRNA-transfected group compared to mock-transfected and control siRNA groups.

NANOG mRNA levels are markedly downregulated in HepG2 cells treated with NANOG siRNA.

Western blot analysis and subsequent quantification confirmed that this reduction translated to the protein level, with a significant drop in NANOG protein expression (P<0.05).

NANOG protein expression is significantly reduced following siRNA transfection, as shown by Western blot (C) and quantified relative expression (D).

Enhanced Chemosensitivity and Reduced MDR1

The most significant finding was the correlation between NANOG and MDR1. When NANOG was knocked down, MDR1 expression at both mRNA and protein levels also decreased significantly. This molecular change resulted in enhanced chemosensitivity; in the presence of doxorubicin (1 µg/ml), NANOG-silenced cells showed roughly 10% viability at 48 hours, whereas controls remained near 30-35%.

Impact on Proliferation and Migration

Knocking down NANOG also made the cells less aggressive. The colony formation rate dropped to 8.5 ± 3.6%, compared to approximately 18% in controls. Furthermore, cell migration was cut by more than half, with only ~49 cells migrating in the knockdown group versus ~107 in the control groups.

Discussion

These results reinforce the Cancer Stem Cell (CSC) hypothesis. NANOG, a master regulator of pluripotency, appears to help cancer cells gain stem-like qualities, including the ability to survive chemotherapy via MDR1-mediated drug efflux. The study establishes a clear link between NANOG silencing and the downregulation of MDR1, although the exact signaling pathway—whether direct or indirect—remains to be detailed in future work.

Conclusion

Knockdown of NANOG in HepG2 human liver cancer cells results in decreased MDR1 expression and increased sensitivity to doxorubicin. These findings suggest that NANOG is a critical regulator of multidrug resistance in liver cancer and could serve as a novel therapeutic target to improve the efficacy of chemotherapy.

Summary updated

Abstract

Multidrug resistance (MDR) is one of the major reasons for the failure of liver cancer chemotherapy, and its suppression may increase the efficacy of chemotherapy. NANOG plays a key role in the regulation of embryonic stem cell self-renewal and pluripotency. Recent studies reported that NANOG was abnormally expressed in several types of tumors, indicating that NANOG is related to tumor development. However, the correlation between NANOG and liver cancer chemoresistance remains uncertain. In this study, RNA interfere technology was employed to knock down NANOG expression in HepG2 human liver cancer cells. We found that the knockdown of NANOG expression in NANOG siRNA-transfected HepG2 cells resulted in decreased colony formation rate and cell migration compared to control HepG2 cells. In addition, HepG2 cells were treated with doxorubicin to evaluate the chemosensitivity to doxorubicin. We found that the doxorubicin sensitivity of HepG2 cells was increased with downregulation of NANOG expression. The expression of MDR1 at both mRNA and protein levels was decreased in HepG2 cells when NANOG was knocked down. These findings suggest that the knockdown of NANOG in HepG2 human cells resulted in decreased MDR1 expression and increased doxorubicin sensitivity, and NANOG could be used as a novel potential therapeutic target to reverse multidrug resistance of liver cancer.
BibTeX
@article{zhou2014knockdown,
  author = {Jiajia Zhou and Xiaogeng Deng and Xiaoyu He and Yu Zhou and Min Yu and Wenchao Gao and Bing Zeng and Quanbo Zhou and Zhihua Li and Rufu Chen},
  title = {{Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression}},
  journal = {International Journal of Oncology},
  year = {2014},
  doi = {10.3892/ijo.2014.2347},
}
Figure